*T* *[oxoplasma]{.smallcaps} gondii* is an obligate intracellular protozoan parasite that is the leading cause of focal central nervous system infections in HIV-infected patients. This parasite is capable of invading and replicating within all nucleated mammalian cells. *T. gondii* resides intracellularly within a vacuole that neither acidifies nor fuses with organelles of the endocytic cascade (for review see [@B49]). The intracellular parasite secretes prodigious amounts of proteins into the vacuolar space enclosed by the parasitophorous vacuolar membrane (PVM),^1^ which surrounds the parasite inside cells (for review see [@B47]). These secreted proteins associate with the PVM, with a tubuloreticular network in the vacuolar space ([@B45]), or with both.

*T. gondii* and related Apicomplexan parasites (e.g., Plasmodia, Cryptosporidia, Sarcocystis, Eimeria) contain three morphologically distinct secretory organelles (rhoptries, micronemes, and dense granules), providing a particularly interesting model for studying secretory granule targeting. Dense granules are 200-nm organelles localized throughout the parasite (for review see [@B11]). In contrast to the anterior rhoptries and micronemes, organelles that discharge at the time of invasion ([@B38]), dense granule exocytosis is thought to occur primarily after invasion, and to continue during the intracellular residence of the organism ([@B20]; [@B9]).

10 dense granule proteins are identified in *T. gondii*: GRA1--GRA7, two isoforms of the nucleoside triphosphate hydrolase (NTPase), and cyclophilin 18 (for reviews see [@B11]; [@B47]). Except for cyclophilin 18, these proteins not only lack significant homology with other proteins in the data base, but they also bear limited amino acid sequence homology with one another. No common sequences are identified that might target these proteins to dense granules. GRA4, GRA5, GRA6, and GRA7 contain putative transmembrane domains, yet all are secreted into the vacuolar space and localize to the vacuolar network (GRA4 and GRA6), to the PVM (GRA5), or to both (GRA7). In contrast, the five major surface proteins of *T. gondii*, including SAG1, are anchored to the plasma membrane by glycosylphosphatidylinositol (GPI) membrane anchors ([@B34]; [@B52]) and are not found in the vacuolar space. The vesicles transporting GPI-anchored proteins to the parasite plasma membrane are not identified.

While there is little precedent for understanding protein sorting events to secretory organelles and to the vacuolar space in *T. gondii* or in any other pathogenic protozoan parasite ([@B2]), all secreted proteins in higher eukaryotic cells, whether soluble or membrane associated, follow an identical pathway from the endoplasmic reticulum to the TGN ([@B7]). In secretory cells, immature secretory granules (ISG) form in the *trans*-Golgi and are sorted at that point from constitutive secretory vesicles (CSV) (for review see [@B54]). Soluble and membrane granule proteins accumulate in ISG, either by signals mediating entry or by signals mediating retention. Motifs within the ectodomain or cytoplasmic tail of transmembrane proteins may confer information for targeting to or removal from ISG during their formation and subsequent maturation to mature secretory granules (MSG) ([@B17]; [@B13]; [@B33]; [@B18]; for review see [@B54]). GPI-anchored proteins may also be components of secretory granules through signals contained in the ectodomain ([@B14]).

To explore the population of vesicles that transport soluble proteins in *T. gondii*, the parasite was stably transformed with the genes for two soluble foreign secretory reporters, *E. coli* β-lactamase (BLA) and *E. coli* alkaline phosphatase (BAP), which should not contain targeting information for delivery to secretory granules. Surprisingly, both reporters localized quantitatively to parasite dense granules, allowing subsequent analysis of targeting signals conferred by addition of membrane anchoring domains to BAP.

Materials and Methods {#MaterialsMethods}
=====================

Buffers
-------

Buffers, including PBS, artificial intracellular salt solution (AISS), electroporation buffer, lysis buffer, and immunoprecipitation wash buffer, were as reported earlier ([@B37]; [@B40]; [@B3]). For secretion assays, AISS buffer with 1× vitamin/amino acid mix (RPMI-1640 Select Amine Kit; GIBCO BRL, Gaithersburg, MD), 5 mM ATP, and protease inhibitors (1 mM PMSF, 5 μM leupeptin, 1 μM aprotinin, 5 μM pepstatin, and 100 μg/ml chymostatin) was used. Biotinylation buffer consisted of 10 mM triethanolamine, pH 9.0, 2 mM CaCl~2~, 150 mM NaCl.

Reagents
--------

Restriction endonucleases, T4 polymerase, and DNA ligase were from New England Biolabs (Beverly, MA). Taq polymerase was from Perkin-Elmer Cetus (Norwalk, CT). DNA sequenase version 2.0 dideoxy chain termination kit was from U.S. Biochemical (Cleveland, OH). Geneclean II was from Bio 101 (La Jolla, CA). Rabbit antibacterial alkaline phosphatase (BAP) and anti-BLA were from 5 Prime → 3 Prime (Boulder, CO). Methionine-free DME and was from GIBCO BRL. Pro-mix [l]{.smallcaps}-^35^S in vivo cell labeling mix and ECL detection kit were from Amersham Corp. (Arlington Heights, IL). Protein A--Sepharose CL-4B was from Pharmacia Biotech (Piscataway, NJ). Phospholipase C was stored at −20°C in 10 mM Tris, pH 7.5 with 50% glycerol (ICN Pharmaceuticals, Aurora, OH). NHS-SS-biotin, stored at 200 mg/ml in DMSO, and streptavidin beads were from Pierce Chemical Co. (Rockford, IL). All other chemicals were from Sigma Chemical Co. (St. Louis, MO).

Growth of Parasites in Mice and Tissue Culture Cells
----------------------------------------------------

*T. gondii* RH strain tachyzoites lacking hypoxanthine-guanine-xanthine phosphoribosyl transferase (provided by D. Roos, University of Pennsylvania, Philadelphia, PA) were maintained by serial passage in the peritoneum of Swiss-Webster mice or by in vitro culture in Vero cells or human foreskin fibroblasts as previously described ([@B4]). Parasites stably expressing BAP or BLA were maintained by serial passage in host cells at 37°C in medium containing 25 μg/ml mycophenolic acid and 50 μg/ml xanthine. RH strain tachyzoites expressing BAP-GPI, BAP-GRA4 constructs, and BAP-G constructs together with the dihydrofolate reductase (DHFR) gene were maintained in medium containing 1 μM pyrimethamine.

Plasmid Constructs
------------------

All secretion reporters were initially cloned into the plasmid pNTP/sec ([@B26]) for transient expression. This vector contained the 5′ untranslated region (UTR) and 3′ UTR and NH~2~-terminal signal sequence from the gene for the *T. gondii* NTPase, an endogenous dense granule protein, as well as an AvrII/BglII cloning site (Fig. [1](#F1){ref-type="fig"} *A*).

For the BAP construct, an AvrII/BglII fragment coding for residues 23--449 of the BAP sequence was amplified from plasmid pHI ([@B24]). For the BLA gene, an AvrII/BglII fragment coding for BLA was amplified from pBluescript. For the BAP-GPI construct, a PstI/BglII fragment of SAG1 coding for residues 287--319 was amplified from *T. gondii* genomic DNA ([@B6]). The digested and purified PCR product together with an AvrII/PstI fragment of BAP were cloned into pNTP/sec cut with AvrII and BglII. BAP-GRA4 was of similar design and contained residues 275--345, encoding the putative transmembrane domain and cytoplasmic tail, fused downstream of BAP. The GRA4 fragment was amplified from genomic DNA ([@B31]). The BAP-GRA4^tail−^ construct was made by introducing a stop codon at residue 298 of the GRA4 domain. BAP-GRA4^Y332A^ was prepared by mutating codon 332 from tyrosine to alanine. BAP-G contained residues 464--511 from the vesicular stomatitis virus G (VSV-G) protein, encoding the transmembrane domain and cytoplasmic tail, introduced downstream of BAP. The VSV-G fragment was amplified from pSVGL1 ([@B43]) and cloned with an AvrII/PstI fragment of BAP into pNTP/Sec. To make BAP-G^tail−^, a stop codon was introduced at codon 489 of the VSV-G tail to yield a protein with five cytoplasmic residues. BAP-G^Y501A^ was constructed by mutating codon 501 (coding for tyrosine) of the VSV-G tail to code for alanine ([@B51]).

Plasmids for stable transfection were prepared by digesting the above constructs with SpeI. The SpeI fragments were subcloned into the SpeI site of pminCAT/HXGPRT or pDHFR-TSc3 containing the mutated DHFR gene conferring pyrimethamine resistance (kindly provided by D. Roos) ([@B19]), as described earlier ([@B26]).

Primers
-------

All primers are 5′ to 3′. [BAP-AvrII/BglII]{.ul}: CGC CTA GGG ACA CCA GAA ATG CCT GTT C and CGG AGA TCT TTA TTT TCA GCC CCA GGG. [BLA]{.ul}: GAA GCC TAG GCC ACC CAG AAA CGC TGG TG and GGA AGA TCT TAC CAA TGC TTA ATG AG. [BAP-AvrII/ PstI]{.ul}: CGC CTA GGG ACA CCA GAA ATG CCT GTT C and GGC TGC AGC TTT CAG CCC CAG GGC GGC. [SAG1]{.ul}: GGG GCT GCA GGG TCA GCA and GGA GAT CTC ACG CGA CAC AAG CTG CG. [GRA4]{.ul}: GGT CGC TGC AGG AAT CCT GAC GGG and CAG AGA TCT CAC TCT TTG CGC TTG CGC ATT C. [BAP-GRA4]{.ul} ^tail−^: GCC AAG ATC TCA CTT GAC AGC CTT TGC. [BAP-GRA4]{.ul} ^Y332A^: GAG AGA TCT CAC TCT TTG CGC ATT CTT TCC AAA TCC TTC AAT AAC TCG GCG GGT GAG GGT CGC GGG. [VSV-G]{.ul}: TTC ACT GCA GGC AAA AGC TCT ATT GCC and GCA GAT CTT ACT TTC CAA GTC GGT TC. [BAP-G]{.ul} ^tail−^: CGA AAT TAA ATT CTA GAG TTA CCT ATG G. [BAP-G]{.ul} ^Y501A^: GCA GAT CTT ACT TTC CAA GTC GGT TCA TCT CTA TGT CTG TAG CAA TCT GTC TTT T.

Transfection and Selection of Stable Lines
------------------------------------------

Transient transfection was performed as described ([@B40]). Plasmid DNA for transfection was isolated using Qiagen plasmid kits (Chatsworth, CA). For preparation of stable lines, electroporated parasites were cultured in Vero or HFF cells in selection media and then cloned by growth under soft agar as described earlier ([@B26]). A 10-cm Petri dish containing Vero cells was infected with about 200 parasites and incubated at 37°C for 20 h. The monolayer was washed three times with PBS^++^ (plus Mg^2+^ and Ca^2+^) and replaced with a mixture of 2× Vero medium plus either 2 μM pyrimethamine or 50 μg/ml mycophenolic acid and 100 μg/ml xanthine and warm 1.6% agarose (43°C). Dishes were incubated until colonies appeared, and then clones were picked and expanded.

Immunofluorescence and Immunoelectron Microscopy
------------------------------------------------

Immunofluorescence on infected cells or extracellular parasites was done as previously reported ([@B25]). Detection was performed with rabbit anti-BAP (1:500) or anti-BLA (1:100) and mouse monoclonal antibodies to GRA3 (T62H11) or GRA2 (T41F51D10) diluted 1: 250 in PBS containing 3% BSA, followed by FITC-conjugated goat anti--rabbit IgG and rhodamine-conjugated goat anti--mouse IgG diluted 1:500 in PBS containing 3% BSA. Coverslips were mounted with Mowiol and observed with an epifluorescence microscope (model Microphot FXA; Nikon, Inc., Melville, NY). Images were captured with a CCD camera (Photometrics, Tuscon, AZ) and processed with Image-Pro Plus (Media Cybernetics, Silver Spring, MD).

For immunoelectron microscopy, monolayers of Vero cells were infected with transgenic *T. gondii* for 24 h. Infected cells were processed, and sections for immunoelectron microscopy were prepared as previously described ([@B4]). Sections were labeled with rabbit anti-BAP (1:250), rabbit anti-BLA (1:100), and mouse anti-SAG1 (T41E5) (1: 2,000) antibody in PBS containing 10% BSA.

SDS-PAGE and Immunoblot
-----------------------

SDS-PAGE and immunoblot were performed according to [@B29] and Towbin (1979). Immunoblots were developed using rabbit anti-BAP (1:5,000), rabbit anti-BLA (1:1,000), mouse anti-SAG1 (1:1,000), or rabbit anti--cross-reacting determinant (CRD, 1:2,000) (provided by P. Englund, Johns Hopkins University, Baltimore, MD) ([@B1]) followed by goat anti--rabbit IgG-HRP or goat anti--mouse IgG-HRP conjugate (1:2,000), and the ECL detection system (Amersham Corp.).

Quantitation of BLA Released from Extracellular Parasites Treated with Brefeldin A
----------------------------------------------------------------------------------

BLA release from extracellular parasites treated with brefeldin A (BFA) was quantitated by enzymatic assay. Six 10-cm Vero dishes with 2--3 × 10^7^ BLA-expressing parasites, or three 10-cm uninfected Vero dishes as control, were incubated at 37°C for 36--40 h. BFA (50 μg/ml) was added to three infected dishes, and incubation was continued at 37°C for 60 min. A high concentration of a BFA was required to completely disperse the *T. gondii* Golgi complex, as assessed by immunofluorescence microscopy antiserum (kindly provided by G. Wood, University of Vermont, Burlington, VT) and G. Langsley (Institut Pasteur, Paris, France) to *Plasmodium falciparum* Rab6. Plates were then put on ice and washed three times with cold secretion buffer. The monolayer was scraped into cold buffer and passed twice through a 27-gauge needle. Then parasites were harvested by centrifugation at 1,450 *g* for 5 min at 4°C. Parasites were washed 3× at 4°C with secretion buffer. To a total of 2 × 10^8^ extracellular parasites in 1 ml, BFA (20 μg/ml) was added for previously BFA-treated parasites. After incubation at 37°C for 0, 30, 60, and 120 min, 250-μl aliquots were removed and spun at 7,000 rpm for 10 min at 4°C, and the supernatant was transferred to a fresh tube. BLA enzymatic activity in the supernatant was quantitated using described procedures ([@B30]) with modifications ([@B26]).

Surface Delivery of SAG1 in the Presence and Absence of BFA
-----------------------------------------------------------

Delivery of SAG1 to the parasite surface, with or without BFA treatment, was assessed by biotinylation. Infected monolayers (24 h) were suspended in 2 ml/dish methionine and cysteine-free DME with or without 50 μg/ml BFA. After incubation at 37°C for 1 h, 125 μCi pro-mix [l]{.smallcaps}-^35^S in vivo cell labeling mix was added to each dish. Incubation was continued at 37°C for another 60 min, and parasites were liberated as described above.

For surface biotinylation, the parasite pellet was suspended in NHS-SS-biotin (1.5 mg/ml) in biotinylation buffer at 4°C for 30 min with very gentle agitation. Parasites were centrifuged at 1,450 *g* at 4°C for 5 min and then resuspended in 1 ml PBS^2+^ with 100 mM glycine and incubated at 4°C for 20 min to quench unreacted biotin.

For immunoprecipitation, parasite pellets were washed, suspended in lysis buffer, and precleared on protein A--Sepharose. To precleared lysates, 5 μl mouse anti-SAG1 (T41E5) and 100 μl protein A--Sepharose beads were added, and incubation continued at 4°C overnight. After washing, the beads were divided into two samples. For surface SAG1 quantification, 100 μl 1% SDS in 50 mM Tris-Cl, pH 7.5, 100 mM NaCl was added, and incubation was continued at 80°C for 10 min to elute bound SAG1. 900 μl lysis buffer was added to the beads, which were centrifuged at 1,500 rpm for 5 min, and the supernatant was transferred to a fresh tube containing 30 μl packed streptavidin beads. After overnight incubation at 4°C, beads were washed. Both total (protein A--Sepharose) and surface SAG1 (streptavidin beads) were quantitated by SDS-PAGE autoradiography and PhosphorImager analysis.

Phospholipase C Treatment
-------------------------

The presence of the GPI anchor was assessed by digestion with phosphatidylinositol-specific phospholipase C (PI-PLC). Parasites were harvested from infected monolayers and washed 3× in cold MEM without FCS. 1.5 × 10^7^ RH strain--, BAP-, or BAP-GPI--expressing parasites were incubated with 0.1 U PI-PLC (ICN Biomedicals, Costa Mesa, CA) in MEM or in MEM without the enzyme for 1 h at 37°C. The reaction volume was 30 μl. Treated parasites were recovered by centrifugation (5 min, 1,450 *g*, 4°C), and the supernatants were saved. The cells were washed three times in MEM and then lysed in 30 μl SDS loading buffer. All samples were analyzed by SDS-PAGE and immunoblot.

Subcellular Fractionation of Infected Cells
-------------------------------------------

Vero cell monolayers were infected with parasites expressing BAP, BAP-GPI, or BAP-G for 20--40 h. Plates were put on ice and then washed three times with PBS with protease inhibitors. The monolayer was scraped into buffer and passed twice through a 27-gauge needle. The parasites were harvested by centrifugation at 1,450 *g* for 5 min at 4°C. The supernatant was centrifuged at 10,000 *g* for 10 min at 4°C to pellet (10K pellet) the bulk of the intravacuolar network and any partially disrupted parasites ([@B37]). The supernatant was centrifuged at 100,000 *g* for 60 min at 4°C to pellet the remaining network (100K pellet). Proteins within the 100,000 *g* supernatant (100K supernatant) were precipitated with trichloroacetic acid. All fractions were analyzed by SDS-PAGE and immunoblot.

Results {#Results}
=======

E. coli Alkaline Phosphatase and β-Lactamase Are Stably Expressed in T. gondii Tachyzoites
------------------------------------------------------------------------------------------

Both soluble BAP and BLA were stably expressed in *T. gondii.* As shown in Fig. [1](#F1){ref-type="fig"} *B*, BAP and BLA were readily detected by immunoblot in extracellular tachyzoites. Both reporters were of the expected size after signal sequence cleavage and comigrated with the endogenous protein expressed in *E. coli* (not shown), indicating that neither proteolysis, inappropriate processing, nor significant posttranslational modifications occurred in *T. gondii.*

BAP and BLA Localize to Dense Granules by Immunofluorescence and Immunoelectron Microscopy
------------------------------------------------------------------------------------------

Within intracellular parasites, both BAP and BLA localized by immunofluorescence to discrete punctate structures consistent with dense granules (Fig. [1](#F1){ref-type="fig"} *C*). Dense granule localization was confirmed by colocalization of the BAP and BLA signals with the endogenous dense granule proteins GRA2 and GRA3.

Localization of BAP and BLA to dense granules was confirmed by immunoelectron microscopy (Fig. [1](#F1){ref-type="fig"}, *D* and *E*). Both BAP (Fig. [1](#F1){ref-type="fig"} *D*) and BLA (not shown) also associated with the intravacuolar network within the parasitophorous vacuole space, suggesting that localization of soluble proteins to the network morphologically does not depend upon parasite-specific sequences.

Release of BLA from T. gondii Dense Granules Is Not Blocked by Brefeldin A
--------------------------------------------------------------------------

These results suggest that the pathway for soluble secretory proteins in *T. gondii* is to dense granules. They do not, however, preclude the simultaneous delivery of soluble secretory proteins into more typical CSV, which also carry soluble cargo to and fuse with the plasma membrane. These vesicles are generally difficult to detect by electron microscopy because of their low abundance, presence in a background of membrane structures, and low concentration of cargo.

We distinguished between these possibilities using BFA. Secretion from preformed dense core granules is not blocked by BFA ([@B42]), whereas CSV, which move rapidly to the plasma membrane, are depleted in the presence of the drug. There was no significant effect on BLA secretion after 1 h of treatment with BFA (Fig. [2](#F2){ref-type="fig"} *A*). Under these same conditions, BFA did block vesicular transport in the parasite, since delivery of the GPI-anchored surface protein SAG1 to the parasite plasma membrane was inhibited by over 85% (Fig. [2](#F2){ref-type="fig"} *B*). Taken together, these results suggest that soluble BAP and BLA are quantitatively delivered to dense granules.

Addition of a GPI Anchor to BAP Results in Expression on the Plasma Membrane
----------------------------------------------------------------------------

We therefore tested whether a GPI anchor was sufficient to route BAP out of dense granules and into CSV. The 33 residue GPI anchor addition site from SAG1 was added to the COOH terminus of BAP (Fig. [3](#F3){ref-type="fig"} *A*). Alkaline phosphatase with a GPI anchor (BAP-GPI) was clearly expressed on the surface of *T. gondii* as shown by immunofluorescence microscopy (Fig. [3](#F3){ref-type="fig"} *B*). Immunoelectron microscopy showed colocalization of BAP-GPI with the surface antigen SAG1 (Fig. [3](#F3){ref-type="fig"}, *C* and *D*). No localization to dense granules was found, whereas both BAP-GPI and SAG1 were detected in association with the membrane at the periphery of large electron-lucent vesicles of larger than 500 nm in diameter (Fig. [3](#F3){ref-type="fig"} *D*).

We confirmed that BAP-GPI was linked to the plasma membrane of *T. gondii* by a GPI anchor (Fig. [4](#F4){ref-type="fig"}). Parasites expressing BAP-GPI were treated with PI-PLC, and the release of BAP containing the CRD, indicative of cleavage of a GPI-membrane anchor, was demonstrated by immunoblot.

Taken together with the results in Figs. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}, these data indicate that a GPI anchor is sufficient to target proteins to the plasma membrane in *T. gondii*, and that the predominant pathway for GPI-anchored proteins is to the plasma membrane.

Addition to BAP of the Putative Transmembrane Domain and Cytoplasmic Tail from GRA4 Results in Delivery to Dense Granules and Secretion into the Vacuolar Space
---------------------------------------------------------------------------------------------------------------------------------------------------------------

We next fused BAP to the putative transmembrane domain and tail from GRA4 ([@B31]), one of four dense granule proteins in *T. gondii* that contain a linear stretch of hydrophobic amino acids near the COOH terminus (Fig. [5](#F5){ref-type="fig"} *A*). While predicted to be a type I integral membrane protein (and one of only a handful of such proteins identified to date in the organism), endogenous GRA4 is nonetheless secreted into the vacuolar space in association with the intravacuolar network.

BAP-GRA4 localized to dense granules (Fig. [5](#F5){ref-type="fig"} *B*, *arrows*; Fig. [5](#F5){ref-type="fig"} *D*) and was secreted in large amounts into the vacuolar space (Fig. [5](#F5){ref-type="fig"} *C*, *arrowheads*) in association with the intravacuolar network (Fig. [5](#F5){ref-type="fig"} *D*). BAP-GRA4 was also detected by immunoelectron microscopy at the parasite plasma membrane (Fig. [5](#F5){ref-type="fig"} *D*), suggesting that delivery into the vacuolar space followed fusion of dense granules with the plasma membrane.

Truncating the GRA4 Cytoplasmic Tail Blocks Delivery to the Vacuolar Space
--------------------------------------------------------------------------

Truncating the cytoplasmic tail of GRA4 four residues downstream of the putative transmembrane domain to generate BAP-GRA4^tail−^ did not alter localization to dense granules (Fig. [5](#F5){ref-type="fig"} *B*), but the chimera was not secreted efficiently into the vacuolar space (Fig. [5](#F5){ref-type="fig"} *C*). In contrast, a Y332A substitution within a potential tyrosine-based sorting motif (Fig. [5](#F5){ref-type="fig"} *A*, *YAEL*) in the GRA4 cytoplasmic tail had no effect on localization to dense granules (Fig. [5](#F5){ref-type="fig"} *B*) or secretion into the vacuolar space (Fig. [5](#F5){ref-type="fig"} *C*).

Addition to BAP of the VSV-G Transmembrane Domain and Cytoplasmic Tail Results in Accumulation within the Golgi
---------------------------------------------------------------------------------------------------------------

To determine whether the localization observed with BAP-GRA4 and mutants was seen with a foreign transmembrane domain and cytoplasmic tail, we added these regions from VSV-G to BAP to generate BAP-G (Fig. [6](#F6){ref-type="fig"} *A*). BAP-G localized to a crescent-shaped structure anterior to the nucleus (Fig. [6](#F6){ref-type="fig"} *B*, *BAP-G*, *arrows*), confirmed by immunoelectron microscopy to be the parasite Golgi (Fig. [6](#F6){ref-type="fig"} *D*). BAP-G was detected to a lesser extent in vesicular structures containing GRA3. Dense granule localization was confirmed by immunoelectron microscopy (Fig. [6](#F6){ref-type="fig"} *E*). BAP-G also localized to the vacuolar space, but not to the vacuolar membrane (Fig. [6](#F6){ref-type="fig"} *C*, *BAP-G*, *arrowhead*). The BAP-G signal was detected by electron microscopy at the plasma membrane and in the intravacuolar network (Fig. [6](#F6){ref-type="fig"}, *D* and *E*).

Partial deletion of the VSV-G cytoplasmic tail alters localization of BAP-G. Motifs in the VSV-G tail dictate either forward transport from the ER to Golgi ([@B36]), or basolateral targeting in polarized epithelial cells ([@B51]). We therefore truncated the VSV-G tail five residues downstream of the transmembrane domain (Fig. [6](#F6){ref-type="fig"} *A*, *BAP-G^tail−^*). This construct localized to vesicular structures containing GRA3 (Fig. [6](#F6){ref-type="fig"} *B*, *BAP-G^tail−^*). No staining was detected in the region of the parasite Golgi. The BAP-G^tail−^ chimera was not detected in the vacuolar space (Fig. [6](#F6){ref-type="fig"} *C*, *BAP-G^tail−^*). Substitution of the single tyrosine within the VSV-G tail to alanine (Fig. [6](#F6){ref-type="fig"} *A*, *BAP-G^Y501A^*) did not eliminate Golgi staining but generally resulted in more extensive delivery of the chimera to vesicular structures containing GRA3 (Fig. [6](#F6){ref-type="fig"} *B*, *BAP-G^Y501A^*) when compared with BAP-G.

Taken together with the data for BAP-GRA4 and mutants, these results suggest that the cytoplasmic tail and transmembrane domain of an endogenous dense granule protein is either permissive for or mediates targeting to dense granules. The cytoplasmic tail from a nondense granule protein (VSV-G) influences either delivery to or retention within *T. gondii* dense granules. Finally, the cytoplasmic tail of both an endogenous and a foreign protein are necessary for efficient secretion into the vacuolar space.

Subcellular Fractionation of BAP, BAP-GPI, and BAP-G Confirms Their Microscopic Localization
--------------------------------------------------------------------------------------------

The behavior of BAP, BAP-GPI, and BAP-G was examined after subcellular fractionation of infected host cells (Fig. [7](#F7){ref-type="fig"}). All reporter proteins were found in large amounts in the 1,450-*g* parasite pellet, as expected. Of the material not sedimenting with parasites, BAP partitioned predominantly into the 100,000-*g* supernatant. In contrast, both BAP-GPI and BAP-G partitioned predominantly into the 10,000-*g* pellet, containing a portion of the intravacuolar network and lysed parasite ghosts. Neither was detected in the 100,000-*g* supernatant. Thus, all reporters behaved as expected based on their predicted sequence and microscopic localization.

Discussion {#Discussion}
==========

We examined sorting of secreted soluble and membrane proteins in the pathogenic protozoan parasite *Toxoplasma gondii*. While the protein targeting processes within the parasite could be construed as novel, they are also interpretable as simplified and/or exaggerated versions of sorting mechanisms used by mammalian cells. This is the interpretation we favor, as explained below. In contrast, targeting of membrane proteins beyond the confines of the organism and into the surrounding vacuolar space involves unusual sorting events.

Two principle models are suggested to account for delivery of soluble proteins into immature secretory granules budding from the TGN of higher eukaryotic cells: (*a*) The "sorting for entry"/active sorting model invokes binding of proteins to a secretory granule receptor or acceptor protein that is concentrated in the TGN and mediates delivery to the ISG ([@B41]; [@B15]). (*b*) The "sorting by retention"/passive sorting model postulates that preferential aggregation of granule proteins, often induced by low pH and high calcium concentrations ([@B12]; [@B14]), occurs within the ISG, retaining the proteins in the forming granule. In this model, both "constitutive" and "regulated" proteins enter ISG, but the former are removed by a vesicular budding process, generating constitutive secretory vesicles. There is growing evidence to support this model in both endocrine and exocrine cells ([@B27], [@B28]; [@B10]). Vesicle budding from ISG is thought to be a mechanism to remove excess membrane from the granule during the condensation process leading to formation of MSG. Since neither we nor others have observed structures compatible with ISG in *T. gondii*, and since budding from ISG is a BFA-sensitive process ([@B16]; [@B21]), it is possible that retention of soluble secreted proteins in *T. gondii* dense granules reflects the absence of substantial vesicle budding from these structures during their biogenesis. Our results are compatible with a simplified view of the passive sorting model for delivery of soluble proteins to dense granules in *T. gondii*, in which all soluble proteins are delivered to dense granules and retained by limiting the options for removal.

Could sorting of soluble proteins to dense granules be a consequence of the timing of dense granule gene expression (e.g., sorting by timing \[[@B8]\])? This is unlikely for several reasons: (*a*) Dense granules are present in *T. gondii* throughout the cell cycle. (*b*) Soluble BAP expressed under the control of the SAG1 promoter and using the SAG1 signal sequence is still targeted to dense granules (Karsten, V., and K.A. Joiner, unpublished observations), as is a fusion of the green fluorescent protein to the COOH terminus of SAG1 deleted of the GPI anchor attachment site ([@B50]).

Proteins with a GPI anchor are generally transported to the apical cell surface in polarized epithelial cells ([@B5]; for review see [@B39]). It has been suggested that GPI-anchored proteins associate with sphingoglycolipids and form glycolipid rafts in the TGN (for review see [@B48]). These microdomains are thought to form spontaneously above a critical concentration of glycolipids and are somehow configured for apical transport. The most likely explanation for our results is that GPI-anchored proteins in *T. gondii* are transported to the plasma membrane in TGN-derived vesicles, analogous to apical transport vesicles. We cannot, however, exclude the possibility that GPI-anchored proteins are transported initially to dense granules and are subsequently sorted into transport vesicles destined for the plasma membrane. A recent report suggested that SAG1 might form detergent-resistant oligomers when GPI anchored, but to a lesser extent when soluble or when fused to the transmembrane domain of CD46 ([@B44]). Of interest, the SAG1-CD46 chimera was delivered to the cell surface, potentially reflecting association of endogenous SAG1 with SAG1-CD46, although transport vesicles were not identified. In fact, vesicles containing the GPI-anchored surface proteins of *T. gondii* have not been previously identified by either morphologic or biochemical techniques. Given their size (300--500 nm), the large lucent structures in which both SAG1 and BAP-GPI are localized in our study are not likely to be CSV. Of interest, however, is the fact that these structures resemble early endosomes morphologically ([@B22]). Our laboratory has recently identified *T. gondii* rab5 and rab7 homologues (Stedman, T., and K.A. Joiner, unpublished results), suggesting that structures resembling or functioning as early and late endosomes may ultimately be identified in the parasite.

The mechanism for biogenesis of the intravacuolar network is unclear. If the network is generated by vesiculation or tubulation from the plasma membrane ([@B23]), sorting of BAP-GPI from BAP-G and BAP-GRA4 must occur at that location. Our results suggest that the cytoplasmic tails of membrane proteins could contribute to the budding process. While the mechanism for such an event is not clear, it could be analogous to budding of enveloped viruses, which is dependent upon binding of cytosolic core components of the virus to the cytoplasmic tails of envelope glycoproteins (e.g., VSV-G \[[@B55]\]). Alternatively, the network may be released from a multivesicular structure at a specialized posterior invagination of the parasite ([@B46]), in which case sorting mediated by the cytoplasmic tail would occur at an earlier step within the parasite. In either case, there are few precedents for delivery of transmembrane proteins to a membranous network outside cells.

Many transmembrane proteins are sorted out of ISG during maturation to MSG (for review see [@B54]) in a process that typically depends upon sequences in the cytoplasmic tail. For example, the peptidylglycine α-amidating monooxygenase is less efficiently retained in granules as a transmembrane protein than after truncation of the cytoplasmic tail ([@B32]), potentially analogous to our results with BAP-G. Patches of clathrin on ISG likely represent sites of coated vesicle formation directing removal of selected transmembrane proteins, through interaction with specific motifs in the cytoplasmic tail that mediate recruitment of the AP-1 adaptor ([@B18]). The ultimate destination for such vesicles is not known, but could include endosomes, the cell surface, or vesicles recycling back to the TGN. Clathrin-coated vesicles are seen adjacent to the *trans*-most cisternae of the Golgi in *T. gondii* (Tilney, L., D. Roos, and M. Shaw, unpublished observations). While their cargo and destination is unknown, it is conceivable that they could deliver BAP-G back to the TGN in a fashion dependent upon the cytoplasmic tail. In such a model, the GRA4 cytoplasmic tail would not be recognized by this sorting machinery, explaining the efficient delivery of BAP-GRA4 to dense granules.
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BAP

:   bacterial alkaline phosphatase

BFA

:   brefeldin A

BLA

:   bacterial β-lactamase

CRD

:   cross-reacting determinant

CSV

:   constitutive secretory vesicles

DHFR

:   dihydrofolate reductase

GPI

:   glycosylphosphatidylinositol

ISG

:   immature secretory granules

MSG

:   mature secretory granules

NTPase

:   nucleoside triphosphate hydrolase

PI-PLC

:   phosphatidylinositol-specific phospholipase C

PVM

:   parasitophorous vacuolar membrane

UTR

:   untranslated region

VSV-G

:   vesicular stomatitis virus

###### 

BAP and BLA are stably expressed in *T. gondii* tachyzoites and localize to parasite dense granules. (*A*) Organization of the NTPase 5′ UTR containing the promoter ([@B35]), NH~2~-terminal signal sequence (*SS*), and 3′ UTR in the plasmid pNTPSec. AvrII and BglII restriction sites were used for inserting the coding regions of *E. coli* alkaline phosphatase (*phoA*) and β-lactamase (*bla*). (*B*) Expression of the transgenes in single clones from BAP (*a--d*) or BLA (*e--h*) transfected parasites was monitored by SDS-PAGE and immunoblot. Also shown are nontransfected parasites (*RH*) and uninfected Vero cells, indicating no cross-reaction of the antibody with endogenous parasite or cell proteins. (*C*) Phase contrast and corresponding immunofluorescence images of single clones stained with antibody to the endogenous dense granule protein GRA3 or with antibodies to BAP or to BLA. Precise colocalization of GRA3 with BAP or GRA2 with BLA in dense granules is shown (*arrows*). (*D* and *E*) Ultrathin cryosections of intracellular *T. gondii* stably expressing BAP or BLA viewed by immunoelectron microscopy. Gold particles were localized in dense granules (*DG*) (*D*, BAP; *E*, BLA) and the intravacuolar network (*NW*) for BAP (*D*). Bars, 100 nm.
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![Short-term BFA treatment does not block BLA secretion but inhibits SAG1 delivery to the plasma membrane. (*A*) BLA release from extracellular parasites is not blocked by short-term treatment with BFA. Infected monolayers containing BLA-expressing parasites were incubated for 60 min at 37°C with or without BFA, at which point parasites were liberated from the host cells. BLA secreted from the extracellular parasites during continued incubation at 37°C was quantitated by enzymatic assay. There was no difference in the amount of protein released by BFA-treated or untreated parasites. The release over 1 h corresponds to 22--23% of total parasite BLA at time 0. Similar results were observed for release of BAP and the endogenous dense granule protein GRA3 (not shown). (*B*) Delivery of SAG1 to the parasite surface is inhibited by short-term treatment with BFA. Infected monolayers were treated with or without BFA for 1 h to deplete Golgi-derived constitutive secretory vesicles and then metabolically labeled for an additional hour in the continued presence or absence of BFA. Parasites liberated from the infected cells were surface biotinylated. After surface biotinylation, lysed parasites were immunoprecipitated with SAG1 and protein A beads to quantitate the total (*Total* lanes) amount of labeled SAG1 present. In half of the sample, biotinylated SAG1 was determined by releasing bound SAG1 from protein A beads and rebinding to Avidin Sepharose beads (*Surface* lanes). In untreated parasites, 46% of total SAG1 was detected on the parasite surface after 1 h of continuous labeling, whereas less than 7% of total SAG1 was on the surface in BFA-treated parasites.](JCB29303.f2){#F2}

###### 

GPI-anchored alkaline phosphatase localizes to the plasma membrane by immunofluorescence and immunoelectron microscopy. (*A*) Design of BAP-GPI construct showing the addition of the SAG1-GPI anchor addition site to BAP. (*B*) Infected cells containing parasites transfected with BAP-GPI were fixed and permeabilized with either methanol (*MeOH*), which optimizes detection of proteins on the parasite surface or secreted into the vacuolar space, or with paraformaldehyde and Triton X-100 (*PFA/ Tx*), which optimizes staining of dense granules and other organelles within the parasite. Fixed samples were stained with the anti-GRA3 mAb and the anti-BAP antiserum. Note the presence for BAP-GPI of surface staining (*MeOH*, *anti-BAP*), but the absence of dense granule staining (*PFA/Tx*, *anti-BAP*), when compared with staining for GRA3. (*C* and *D*) Cryosections of BAP-GPI--expressing parasites were labeled with antibodies to SAG1 (5-nm gold) and antibodies to BAP (10-nm gold). 5- and 10-nm gold particles colocalize at the plasma membrane (*PM*) and inner membrane complex (*IMC*) of transgenic parasites. In perinuclear areas, membranes of large electron-lucent vesicles (*V*) were labeled with gold particles of both sizes (*C*). Bars, 200 nm.
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![Phospholipase C treatment exposes a CRD epitope in BAP-GPI. RH strain, BAP-expressing, or BAP-GPI--expressing parasites were treated with PI-PLC (+) or incubated in medium (−). After treatment, the parasites were centrifuged, and the resulting supernatants (*S*) and pellets (*P*) were analyzed by SDS-PAGE and immunoblot with antibodies to the CRD ([@B1]), an epitope of the GPI anchor that is exposed only after cleavage with PLC. The CRD epitope was exposed on endogenous parasite proteins released into the supernatant, regardless of whether wild-type RH strain parasites or transgenic parasites expressing BAP or BAP-GPI parasites were tested (lanes *4*, *8*, and *12*). These bands correspond to the endogenous surface proteins SAG1 (30 kD), SAG2 (22 kD), SAG3 (43 kD), p23, and p35. A small amount of SAG1 expressing the CRD epitope was present on the parasite surface after PI-PLC treatment (lanes *2*, *6*, and *10*). In contrast, only BAP-GPI--expressing parasites treated with PI-PLC released BAP into the supernatant (lane *12*).](JCB29303.f4){#F4}

###### 

BAP-GRA4 localizes to dense granules and requires the cytoplasmic tail for efficient secretion into the intravacuolar network. (*A*) Design of BAP-GRA4, BAP-GRA4^tail−^, and BAP-GRA4^Y332A^ constructs, showing addition of the GRA4 transmembrane and cytoplasmic tail to BAP and the two alterations within the tail. All of the constructs behaved as integral membrane proteins when analyzed in a heterologous in vitro translation/translocation system (not shown). (*B*) Infected cells containing parasites expressing BAP-GRA4, BAP-GRA4^tail−^, or BAP-GRA4^Y332A^ were fixed with PFA and permeabilized with Triton X-100 to optimize staining of dense granules and other internal organelles of the parasite. Cells were stained with antibodies to BAP or the dense granule marker GRA3. The BAP signal colocalized with staining for GRA3 in all three chimeras, demonstrating delivery of BAP-GRA4, BAP-GRA4^tail−^, and BAP-GRA4^Y332A^ to dense granules (*arrows*). (*C*) Infected cells containing parasites expressing BAP-GRA4, BAP-GRA4^tail−^, or BAP-GRA4^Y332A^ were fixed with MeOH to optimize detection of proteins secreted into the vacuolar space. Cells were stained with antibodies to BAP or GRA3. The arrowheads show network staining for the BAP-GRA4 and BAP-GRA4^Y332A^ constructs. Only minimal amounts (*arrowhead*) of GRA4^tail−^ were detected in the vacuolar space. (*D*) Cryosections of BAP-GRA4--expressing parasites stained with antibodies to BAP. Gold particles localize primarily to dense granules (*DG*) and the intravacuolar network (*NW*), with some staining of the plasma membrane (*PM*). Bar, 200 nm.
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###### 

BAP-G localizes to the Golgi and requires the cytoplasmic tail for efficient secretion into the intravacuolar network. (*A*) Design of BAP-G, BAP-G^tail−^, and BAP-G ^Y501A^ constructs, showing addition of the VSV-G transmembrane and cytoplasmic tail to BAP and the two alterations within the tail. (*B*) Infected cells containing parasites expressing BAP-G, BAP-G^tail−^, or BAP-G^Y501A^ were fixed with PFA, permeabilized with Triton X-100, and then stained with antibodies to GRA3 or BAP. The arrows show staining of the parasite Golgi for the BAP-G and BAP-G^Y501A^ constructs. Golgi localization was not observed with BAP-G^tail−^. Extensive colocalization of BAP-G^tail−^ and BAP-G^Y501A^ with GRA3 was noted, whereas the extent of dense granule staining for BAP-G was variable and less intense. (*C*) Infected cells containing parasites expressing BAP-G, BAP-G^tail−^, or BAP-G^Y501A^ were fixed with MeOH. Cells were stained with antibodies to BAP or GRA3. Arrowheads show network staining for BAP-G and BAP-G^Y501A^. Network staining for BAP-G^tail−^ was minimal. (*D* and *E*) Cryosections of BAP-G--expressing parasites stained with antibodies to BAP. Gold particles localize primarily to the Golgi (*D*), the plasma membrane (*PM*), and the intravacuolar network (*NW*), with occasional staining of dense granules (*E*, *DG*). Bars, 200 nm.
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![Subcellular fractionation of infected Vero cells containing transgenic *T. gondii* Vero cells infected with *T. gondii* expressing either BAP, BAP-GPI, or BAP-G were disrupted by syringe passage. Intact parasites were pelleted at 1,400 *g* (*1.4K P*), and the supernatant, containing material from the vacuolar space and from disrupted parasites, was subjected to further differential centrifugation. Identical parasite equivalents from the 1.4 K P, 10 K P, 100 K *P,* and 100 K S samples were analyzed by SDS-PAGE immunoblot with antibodies to BAP. Only BAP is a soluble protein in the vacuolar space.](JCB29303.f7){#F7}
